ADMA Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	488.56	426.45	258.22	154.08	80.94	42.22
Revenue Growth (YoY)	27.63%	65.16%	67.58%	90.36%	91.72%	43.85%
Cost of Revenue	221.28	206.9	167.17	118.82	79.77	53.79
Gross Profit	267.28	219.55	91.04	35.27	1.17	-11.57
Selling, General & Admin	96.37	78.37	62.59	70.3	55.19	39.22
Research & Development	3.78	1.81	3.3	3.61	2.85	5.91
Amortization of Goodwill & Intangibles	0.12	0.39	0.72	0.72	0.72	0.72
Operating Expenses	100.27	80.57	66.61	74.63	58.75	45.84
Operating Income	167.02	138.98	24.43	-39.37	-57.57	-57.41
Interest Expense	-8.36	-13.93	-25.03	-19.28	-13.06	-11.99
Interest & Investment Income	1.98	2.1	1.62	0.05	0.04	0.29
Other Non Operating Income (Expenses)	-0.28	-0.19	-0.29	-0.64	-0.25	-0.13
EBT Excluding Unusual Items	160.35	126.96	0.74	-59.23	-70.85	-69.24
Merger & Restructuring Charges	-	-	-	-	-	-7.5
Asset Writedown	-	-	-2.1	-	-	-
Other Unusual Items	-4.58	-1.24	-26.87	-6.67	-0.8	0.99
Pretax Income	155.77	125.71	-28.24	-65.9	-71.65	-75.75
Income Tax Expense	-53.67	-71.96	-	-	-	-
Net Income	209.45	197.67	-28.24	-65.9	-71.65	-75.75
Net Income to Common	209.45	197.67	-28.24	-65.9	-71.65	-75.75
Shares Outstanding (Basic)	238	233	224	198	140	86
Shares Outstanding (Diluted)	246	243	224	198	140	86
Shares Change (YoY)	3.49%	8.65%	13.19%	41.77%	62.03%	58.51%
EPS (Basic)	0.88	0.85	-0.13	-0.33	-0.51	-0.88
EPS (Diluted)	0.86	0.81	-0.13	-0.33	-0.51	-0.88
Free Cash Flow	40.73	110.45	4.03	-73.42	-125.88	-114.73
Free Cash Flow Per Share	0.17	0.45	0.02	-0.37	-0.90	-1.33
Gross Margin	54.71%	51.48%	35.26%	22.89%	1.45%	-27.41%
Operating Margin	34.19%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Profit Margin	42.87%	46.35%	-10.94%	-42.77%	-88.52%	-179.41%
Free Cash Flow Margin	8.34%	25.90%	1.56%	-47.65%	-155.52%	-271.74%
EBITDA	175.01	147.03	32.76	-32.25	-52.08	-53.47
EBITDA Margin	35.82%	34.48%	12.69%	-20.93%	-64.34%	-126.65%
D&A For EBITDA	7.99	8.05	8.33	7.11	5.5	3.94
EBIT	167.02	138.98	24.43	-39.37	-57.57	-57.41
EBIT Margin	34.19%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Revenue as Reported	-	-	-	-	-	42.22

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q